{"gene":"KARS1","run_date":"2026-06-10T01:55:23","timeline":{"discoveries":[{"year":2013,"finding":"KARS1 (lysyl-tRNA synthetase) is expressed in hair cells of zebrafish, chickens, and mice, with strong localization to the spiral ligament region of the cochlea, Deiters' cells, sulcus epithelium, basilar membrane, and spiral limbus surface, consistent with a role in inner-ear aminoacylation.","method":"Immunolocalization/expression analysis in cochlear tissues of multiple species","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct localization experiment across multiple species, but functional consequence of cochlear localization not directly demonstrated","pmids":["23768514"],"is_preprint":false},{"year":2017,"finding":"The KARS1 p.R477H mutation alters protein structure (shown by circular dichroism) and releases LysRS from the multiple-synthetase complex (MSC) without affecting dimer-tetramer oligomerization or cellular distribution; p.R477H and p.P505S mutations each reduce tRNALys aminoacylation activity, with a cumulative effect when combined.","method":"Enzymatic aminoacylation assays, circular dichroism spectroscopy, gel filtration chromatography, immunofluorescence","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal in vitro methods (enzymatic assay, CD, gel filtration) in a single study demonstrating both structural and catalytic consequences of mutations","pmids":["28887846"],"is_preprint":false},{"year":2018,"finding":"The KARS1 p.Pro228Leu variant impairs mitochondrial translation in patient fibroblasts, causing multiple oxidative phosphorylation deficiency; re-introduction of wild-type mitochondrial KARS (but not the cytosolic isoform) rescued the defect, demonstrating that this variant specifically disrupts the mitochondrial isoform's function.","method":"Patient fibroblast molecular characterization, isoform-specific rescue by re-expression, oxidative phosphorylation assay","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean loss-of-function phenotype with isoform-specific rescue experiment providing mechanistic specificity","pmids":["30252186"],"is_preprint":false},{"year":2019,"finding":"Pathogenic KARS1 variants exhibit reduced aminoacylation (tRNA-charging) enzymatic activity in vitro (shown by aminoacylation assays on purified recombinant protein and in patient lymphoblasts/fibroblasts showing ~50% reduction in enzyme activity), establishing loss of catalytic function as a core pathogenic mechanism.","method":"Aminoacylation assays on purified recombinant mutant protein and patient-derived lymphoblasts/fibroblasts","journal":"Neurology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct enzymatic assays on recombinant protein plus patient cell lines with quantitative activity measurements","pmids":["30737337"],"is_preprint":false},{"year":2019,"finding":"KARS1 pathogenic variants (p.Pro228Leu and p.Phe291Val) reduce cytoplasmic KARS protein levels in patient cells and decrease interaction of the cytoplasmic isoform with the multiple aminoacyl-tRNA synthetase complex (MSC); both variants also show decreased aminoacylation activity in vitro.","method":"Western blot, Co-immunoprecipitation (interaction with MSC), in vitro aminoacylation assay","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal functional evidence from patient cells (Co-IP showing reduced MSC interaction) plus in vitro enzymatic assay","pmids":["31116475"],"is_preprint":false},{"year":2019,"finding":"KARS1 missense mutations reduce enzymatic (aminoacylation) activities of LysRS in Xenopus embryo models, and disrupted LysRS causes abnormal CNS development; LysRS is also noted to act as a non-canonical inducer of immune response with transcriptional activity.","method":"Enzymatic assays on mutant LysRS proteins; Xenopus embryo loss-of-function model","journal":"Brain : a journal of neurology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — enzymatic assays plus in vivo Xenopus model, single lab","pmids":["30715177"],"is_preprint":false},{"year":2020,"finding":"KARS1 hearing-impairment mutations (c.1129G>A/p.Asp377Asn and c.517T>C/p.Tyr173His) do not affect LysRS incorporation into the multiple-synthetase complex but alter cytosolic LysRS protein level, tertiary structure, and reduce cytosolic tRNA aminoacylation in vitro; the c.517T>C mutant is completely deficient in charging mitochondrial tRNALys both in vitro and in vivo (yeast model), while c.1129G>A shows less severe mitochondrial charging defect.","method":"In vitro aminoacylation assays (cytosolic and mitochondrial tRNALys), gel filtration (MSC incorporation), yeast genetic complementation models","journal":"Science China. Life sciences","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods including in vitro reconstitution, yeast in vivo complementation, and MSC interaction assay in one study","pmids":["32189241"],"is_preprint":false},{"year":2020,"finding":"A KARS1 mutation (P542R) causes constitutive cytoplasmic mislocalization of LysRS and constitutive activation of MITF (microphthalmia transcription factor), leading to mast cell hyperactivation with increased proinflammatory mediator release; structural dynamics simulations indicate the mutant mimics the active LysRS conformation.","method":"Biochemical assays, Western blot, confocal microscopy, cell transfection, cell degranulation assays, prostaglandin D2 secretion measurement, molecular dynamics simulations","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — functional assays (degranulation, mediator secretion) combined with localization and structural modeling, single lab","pmids":["33385443"],"is_preprint":false},{"year":2021,"finding":"KARS1 biallelic variants affect both cytosolic and mitochondrial LysRS isoform function, demonstrated by variable growth defects in yeast complementation models; detrimental effects of two variants were partially rescued by lysine supplementation, suggesting a role for substrate availability in the pathogenic mechanism.","method":"Yeast complementation assays for cytosolic and mitochondrial isoforms; lysine supplementation rescue experiment","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via yeast complementation with lysine rescue, single lab","pmids":["33942428"],"is_preprint":false},{"year":2024,"finding":"Kars knock-in mice (p.R477H/p.P505S equivalent) display reduced myelination, oligodendrocyte differentiation arrest, increased caspase-3-mediated apoptosis in oligodendrocytes, reduced aminoacylation and steady-state levels of mitochondrial tRNALys, decreased OXPHOS complex subunit expression, reduced Complex IV activity, decreased ATP production, increased ROS, and abnormal mitochondria in white matter oligodendrocytes; melatonin treatment rescued mitochondrial and oligodendrocyte deficits and restored myelination.","method":"CRISPR-Cas9 knock-in mouse model, aminoacylation assays, Complex IV activity assay, ATP/ROS measurement, electron microscopy, immunohistochemistry, melatonin rescue experiment","journal":"Journal of pineal research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vivo knock-in model with multiple orthogonal mechanistic assays (enzymatic, bioenergetic, histological, rescue), single lab","pmids":["39087379"],"is_preprint":false},{"year":2025,"finding":"Kars knockout zebrafish larvae show differential abundance of 420 proteins versus wildtype; the most enriched pathways affected include ribosome, aminoacyl-tRNA biosynthesis, and hypertrophic cardiomyopathy pathways; specific proteins nars, mybphb, atp2a1l, col6a1, and rps3a are linked to kars deficiency.","method":"iTRAQ proteomics on kars knockout zebrafish larvae; parallel reaction monitoring (PRM) validation","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — in vivo knockout with quantitative proteomics, but mechanistic links to individual proteins are correlative","pmids":["40032059"],"is_preprint":false},{"year":2003,"finding":"The human KARS1 gene lies immediately adjacent to the RAP1 (TERF2IP) gene in a head-to-head orientation separated by only ~57 nt; both genes share a bidirectional, TATA-less promoter located in the intergenic spacer with downstream promoter elements (DPEs), a conserved arrangement also found in chicken.","method":"Genomic locus analysis, promoter activity assays (reporter constructs), EST analysis","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct promoter activity assays with reporter constructs plus genomic analysis, conserved across species","pmids":["14659874"],"is_preprint":false},{"year":2023,"finding":"KARS1 mutations impair B cell metabolism, specifically reducing mitochondrial numbers and activity in patient B cells, providing a cellular mechanism for the hypogammaglobulinemia observed in KARS1-related disease.","method":"Functional analysis of patient B cells (mitochondrial number and activity measurements)","journal":"Journal of clinical immunology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single patient cell-based observation, limited mechanistic follow-up reported in abstract","pmids":["37770806"],"is_preprint":false}],"current_model":"KARS1 encodes a dual-localized lysyl-tRNA synthetase (LysRS) that aminoacylates cytosolic and mitochondrial tRNALys with lysine as the first step of protein translation; pathogenic variants reduce aminoacylation activity of one or both isoforms, can disrupt LysRS incorporation into the cytoplasmic multiple aminoacyl-tRNA synthetase complex (MSC), impair mitochondrial translation and oxidative phosphorylation (especially in oligodendrocytes), and in a non-canonical moonlighting role, LysRS translocates to regulate MITF-dependent mast cell activation, with the combination of these canonical and non-canonical dysfunctions underlying a broad disease spectrum including deafness, leukodystrophy, neuropathy, and immune defects."},"narrative":{"mechanistic_narrative":"KARS1 encodes a dual-localized lysyl-tRNA synthetase (LysRS) that charges both cytosolic and mitochondrial tRNALys with lysine, the committed first step of protein translation, and pathogenic variants converge on loss of this aminoacylation activity as a core disease mechanism [PMID:30737337, PMID:32189241]. The cytosolic isoform is incorporated into the multiple aminoacyl-tRNA synthetase complex (MSC), and disease variants act through distinct routes: some (p.R477H) release LysRS from the MSC and reduce charging without altering oligomerization or distribution [PMID:28887846], while others (p.Pro228Leu, p.Phe291Val) lower cytosolic protein levels and weaken MSC interaction [PMID:31116475]. Variants can selectively cripple the mitochondrial isoform, impairing mitochondrial translation and producing combined oxidative phosphorylation deficiency, as shown by isoform-specific rescue with the mitochondrial but not cytosolic protein [PMID:30252186, PMID:32189241]. In an in vivo knock-in mouse model, compound LysRS deficiency arrests oligodendrocyte differentiation, reduces mitochondrial tRNALys aminoacylation, lowers Complex IV activity and ATP, raises ROS, and impairs myelination [PMID:39087379]. Beyond its canonical role, a constitutively active LysRS conformation arising from the P542R variant mislocalizes to the cytoplasm and drives MITF-dependent mast cell hyperactivation and proinflammatory mediator release [PMID:33385443]. These canonical translational and non-canonical signaling functions underlie a phenotypic spectrum spanning hearing impairment, leukodystrophy, and immune defects [PMID:23768514, PMID:37770806].","teleology":[{"year":2013,"claim":"Established that KARS1 is expressed in inner-ear sensory and supporting structures, providing the anatomical rationale for its link to hearing impairment.","evidence":"Immunolocalization/expression analysis in cochlear tissues of zebrafish, chicken, and mouse","pmids":["23768514"],"confidence":"Medium","gaps":["Functional consequence of cochlear localization not directly demonstrated","Does not establish which isoform mediates the ear-specific requirement"]},{"year":2017,"claim":"Resolved that some pathogenic variants act not only by lowering catalysis but by structurally releasing LysRS from the MSC, distinguishing complex-assembly defects from purely enzymatic ones.","evidence":"Aminoacylation assays, circular dichroism, gel filtration, and immunofluorescence on p.R477H and p.P505S mutants","pmids":["28887846"],"confidence":"High","gaps":["Did not test mitochondrial isoform consequences","In vivo phenotype of MSC release not assessed in this study"]},{"year":2018,"claim":"Demonstrated isoform specificity: a variant can selectively disable the mitochondrial LysRS and cause OXPHOS deficiency, settling that the two isoforms are functionally separable in disease.","evidence":"Patient fibroblast characterization with isoform-specific wild-type rescue and OXPHOS assay (p.Pro228Leu)","pmids":["30252186"],"confidence":"High","gaps":["Tissue-specific basis of mitochondrial vulnerability not addressed","Did not test cytosolic translation in same cells"]},{"year":2019,"claim":"Confirmed reduced aminoacylation as the shared core mechanism across pathogenic variants, quantifying ~50% activity loss in patient cells.","evidence":"Aminoacylation assays on purified recombinant protein and patient lymphoblasts/fibroblasts","pmids":["30737337"],"confidence":"High","gaps":["Does not connect residual activity level to phenotype severity","Cytosolic vs mitochondrial contribution not separated"]},{"year":2019,"claim":"Linked variant pathogenicity to both reduced cytosolic protein levels and weakened MSC interaction, and connected enzyme loss to abnormal CNS development in vivo.","evidence":"Western blot, Co-IP for MSC interaction, in vitro aminoacylation (patient cells); Xenopus loss-of-function embryo model","pmids":["31116475","30715177"],"confidence":"High","gaps":["Non-canonical transcriptional/immune role of LysRS noted but not mechanistically dissected here","Causal chain from MSC loss to neurodevelopmental defect not established"]},{"year":2020,"claim":"Showed that hearing-impairment variants spare MSC incorporation but differentially impair cytosolic versus mitochondrial tRNALys charging, mapping genotype to isoform-level deficits.","evidence":"In vitro aminoacylation of cytosolic and mitochondrial tRNALys, gel filtration, and yeast complementation (p.Asp377Asn, p.Tyr173His)","pmids":["32189241"],"confidence":"High","gaps":["Cochlear cell-type basis of deafness not resolved","Relationship between charging deficit magnitude and clinical severity unclear"]},{"year":2020,"claim":"Uncovered a non-canonical mechanism whereby a variant locks LysRS in an active conformation, driving cytoplasmic mislocalization, MITF activation, and mast cell hyperactivation.","evidence":"Biochemical assays, confocal microscopy, degranulation and PGD2 secretion assays, and molecular dynamics simulations (P542R)","pmids":["33385443"],"confidence":"Medium","gaps":["Single lab; in vivo immune phenotype not validated in patients","Molecular link between LysRS and MITF not biochemically defined"]},{"year":2021,"claim":"Established that biallelic variants commonly affect both isoforms and that lysine substrate availability modulates pathogenicity, implicating substrate provision in mechanism.","evidence":"Yeast complementation for cytosolic and mitochondrial isoforms with lysine supplementation rescue","pmids":["33942428"],"confidence":"Medium","gaps":["Lysine rescue only partial and not validated in human cells or in vivo","Single lab"]},{"year":2024,"claim":"Provided in vivo mechanistic integration: LysRS deficiency impairs mitochondrial tRNALys charging and bioenergetics in oligodendrocytes, arresting myelination, with melatonin rescuing the deficits.","evidence":"CRISPR knock-in mouse (R477H/P505S equivalent), aminoacylation, Complex IV/ATP/ROS assays, electron microscopy, immunohistochemistry, melatonin rescue","pmids":["39087379"],"confidence":"High","gaps":["Melatonin mechanism of rescue not fully defined","Generalizability to other cell types and variants untested"]},{"year":2025,"claim":"Mapped the proteome-wide consequences of kars loss in vivo, identifying ribosome and aminoacyl-tRNA biosynthesis pathways as most affected.","evidence":"iTRAQ proteomics with PRM validation on kars knockout zebrafish larvae","pmids":["40032059"],"confidence":"Medium","gaps":["Links to individual proteins are correlative","Causal role of identified proteins in phenotype untested"]},{"year":2023,"claim":"Extended the mitochondrial mechanism to the immune system, linking impaired B cell mitochondrial function to hypogammaglobulinemia in KARS1 disease.","evidence":"Functional analysis of patient B cell mitochondrial number and activity","pmids":["37770806"],"confidence":"Low","gaps":["Single patient cell-based observation with limited mechanistic follow-up","Direct causal link to antibody deficiency not established"]},{"year":null,"claim":"How specific variant-driven balances of cytosolic-MSC, mitochondrial-translation, and non-canonical MITF dysfunction map onto distinct clinical phenotypes remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying genotype-phenotype model across deafness, leukodystrophy, neuropathy, and immune defects","Molecular basis of the LysRS-MITF signaling axis not defined","Tissue-specific vulnerability mechanisms unexplained"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,2,3,6]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[3,6]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[3,6]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[5,7]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,6,7]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2,6,9]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[3,6,10]}],"complexes":["multiple aminoacyl-tRNA synthetase complex (MSC)"],"partners":["MITF","TERF2IP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15046","full_name":"Lysine--tRNA ligase","aliases":["Lysyl-tRNA synthetase","LysRS"],"length_aa":597,"mass_kda":68.0,"function":"Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction: the amino acid (AA) is first activated by ATP to form AA-AMP and then transferred to the acceptor end of the tRNA (PubMed:18029264, PubMed:18272479, PubMed:9278442). When secreted, acts as a signaling molecule that induces immune response through the activation of monocyte/macrophages (PubMed:15851690). Catalyzes the synthesis of the signaling molecule diadenosine tetraphosphate (Ap4A), and thereby mediates disruption of the complex between HINT1 and MITF and the concomitant activation of MITF transcriptional activity (PubMed:14975237, PubMed:19524539, PubMed:23159739, PubMed:5338216) (Microbial infection) Interacts with HIV-1 virus GAG protein, facilitating the selective packaging of tRNA(3)(Lys), the primer for reverse transcription initiation","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/Q15046/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/KARS1","classification":"Common Essential","n_dependent_lines":1208,"n_total_lines":1208,"dependency_fraction":1.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ATG13","stoichiometry":0.2},{"gene":"CAPZB","stoichiometry":0.2},{"gene":"EMC8","stoichiometry":0.2},{"gene":"EMC9","stoichiometry":0.2},{"gene":"NCAPH","stoichiometry":0.2},{"gene":"PSPC1","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/KARS1","total_profiled":1310},"omim":[{"mim_id":"619196","title":"DEAFNESS, CONGENITAL, AND ADULT-ONSET PROGRESSIVE LEUKOENCEPHALOPATHY; DEAPLE","url":"https://www.omim.org/entry/619196"},{"mim_id":"619147","title":"LEUKOENCEPHALOPATHY, PROGRESSIVE, INFANTILE-ONSET, WITH OR WITHOUT DEAFNESS; LEPID","url":"https://www.omim.org/entry/619147"},{"mim_id":"613916","title":"DEAFNESS, AUTOSOMAL RECESSIVE 89; DFNB89","url":"https://www.omim.org/entry/613916"},{"mim_id":"613641","title":"CHARCOT-MARIE-TOOTH DISEASE, RECESSIVE INTERMEDIATE B; CMTRIB","url":"https://www.omim.org/entry/613641"},{"mim_id":"601421","title":"LYSYL-tRNA SYNTHETASE 1; KARS1","url":"https://www.omim.org/entry/601421"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/KARS1"},"hgnc":{"alias_symbol":["KARS2"],"prev_symbol":["DFNB89","KARS"]},"alphafold":{"accession":"Q15046","domains":[{"cath_id":"2.40.50.140","chopping":"106-208","consensus_level":"high","plddt":97.6843,"start":106,"end":208},{"cath_id":"3.30.930.10","chopping":"239-392_459-567","consensus_level":"high","plddt":97.5946,"start":239,"end":567}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15046","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15046-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15046-F1-predicted_aligned_error_v6.png","plddt_mean":90.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=KARS1","jax_strain_url":"https://www.jax.org/strain/search?query=KARS1"},"sequence":{"accession":"Q15046","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15046.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15046/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15046"}},"corpus_meta":[{"pmid":"23768514","id":"PMC_23768514","title":"Mutations in KARS, encoding lysyl-tRNA synthetase, cause autosomal-recessive nonsyndromic hearing impairment DFNB89.","date":"2013","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23768514","citation_count":94,"is_preprint":false},{"pmid":"25330800","id":"PMC_25330800","title":"Congenital Visual Impairment and Progressive Microcephaly Due to Lysyl-Transfer Ribonucleic Acid (RNA) Synthetase (KARS) Mutations: The Expanding Phenotype of Aminoacyl-Transfer RNA Synthetase Mutations in Human Disease.","date":"2014","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/25330800","citation_count":52,"is_preprint":false},{"pmid":"30737337","id":"PMC_30737337","title":"Biallelic variants in LARS2 and KARS cause deafness and (ovario)leukodystrophy.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30737337","citation_count":44,"is_preprint":false},{"pmid":"28887846","id":"PMC_28887846","title":"Mutations in KARS cause early-onset hearing loss and leukoencephalopathy: Potential pathogenic mechanism.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28887846","citation_count":38,"is_preprint":false},{"pmid":"30715177","id":"PMC_30715177","title":"Biallelic KARS pathogenic variants cause an early-onset progressive leukodystrophy.","date":"2019","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/30715177","citation_count":28,"is_preprint":false},{"pmid":"31116475","id":"PMC_31116475","title":"Mutations in KARS cause a severe neurological and neurosensory disease with optic neuropathy.","date":"2019","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/31116475","citation_count":23,"is_preprint":false},{"pmid":"32189241","id":"PMC_32189241","title":"Hearing impairment-associated KARS mutations lead to defects in aminoacylation of both cytoplasmic and mitochondrial tRNALys.","date":"2020","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32189241","citation_count":22,"is_preprint":false},{"pmid":"14659874","id":"PMC_14659874","title":"The telomeric protein Rap1 is conserved in vertebrates and is expressed from a bidirectional promoter positioned between the Rap1 and KARS genes.","date":"2003","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/14659874","citation_count":18,"is_preprint":false},{"pmid":"30252186","id":"PMC_30252186","title":"Inhibition of mitochondrial translation in fibroblasts from a patient expressing the KARS p.(Pro228Leu) variant and presenting with sensorineural deafness, developmental delay, and lactic acidosis.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/30252186","citation_count":18,"is_preprint":false},{"pmid":"33385443","id":"PMC_33385443","title":"Mutation in KARS: A novel mechanism for severe anaphylaxis.","date":"2020","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33385443","citation_count":15,"is_preprint":false},{"pmid":"22733196","id":"PMC_22733196","title":"Management of benign ovarian cysts by a novel, gasless, single-incision laparoscopic technique: keyless abdominal rope-lifting surgery (KARS).","date":"2012","source":"Surgical endoscopy","url":"https://pubmed.ncbi.nlm.nih.gov/22733196","citation_count":15,"is_preprint":false},{"pmid":"33942428","id":"PMC_33942428","title":"Bi-allelic KARS1 pathogenic variants affecting functions of cytosolic and mitochondrial isoforms are associated with a progressive and multisystem disease.","date":"2021","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/33942428","citation_count":14,"is_preprint":false},{"pmid":"11723230","id":"PMC_11723230","title":"A new bis-indole, KARs, induces selective M arrest with specific spindle aberration in neuroblastoma cell line SH-SY5Y.","date":"2001","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11723230","citation_count":13,"is_preprint":false},{"pmid":"21181198","id":"PMC_21181198","title":"DFNB89, a novel autosomal recessive nonsyndromic hearing impairment locus on chromosome 16q21-q23.2.","date":"2010","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21181198","citation_count":11,"is_preprint":false},{"pmid":"37770806","id":"PMC_37770806","title":"Antibody Deficiency in Patients with Biallelic KARS1 Mutations.","date":"2023","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37770806","citation_count":9,"is_preprint":false},{"pmid":"34448181","id":"PMC_34448181","title":"Ketogenic Diet for KARS-Related Mitochondrial Dysfunction and Progressive Leukodystrophy.","date":"2021","source":"Neuropediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/34448181","citation_count":8,"is_preprint":false},{"pmid":"27247904","id":"PMC_27247904","title":"Carriage rate and methicillin resistance of Staphylococcus aureus in food handlers in Kars City, Turkey.","date":"2016","source":"SpringerPlus","url":"https://pubmed.ncbi.nlm.nih.gov/27247904","citation_count":8,"is_preprint":false},{"pmid":"33478492","id":"PMC_33478492","title":"Leopard-like retinopathy and severe early-onset portal hypertension expand the phenotype of KARS1-related syndrome: a case report.","date":"2021","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/33478492","citation_count":7,"is_preprint":false},{"pmid":"33260297","id":"PMC_33260297","title":"Progressive Early-Onset Leukodystrophy Related to Biallelic Variants in the KARS Gene: The First Case Described in Latin America.","date":"2020","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33260297","citation_count":7,"is_preprint":false},{"pmid":"39087379","id":"PMC_39087379","title":"KARS Mutations Impair Brain Myelination by Inducing Oligodendrocyte Deficiency: One Potential Mechanism and Improvement by Melatonin.","date":"2024","source":"Journal of pineal research","url":"https://pubmed.ncbi.nlm.nih.gov/39087379","citation_count":4,"is_preprint":false},{"pmid":"38980148","id":"PMC_38980148","title":"Expansion of the phenotypic spectrum of KARS1-related disorders to include arthrogryposis multiplex congenita and summary of experiences with lysine supplementation.","date":"2024","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/38980148","citation_count":4,"is_preprint":false},{"pmid":"28483727","id":"PMC_28483727","title":"Determining the Prevalence of Cryptosporidium Infections with Acid Fast Staining and ELISA in Calves at the Kars Province of Turkey.","date":"2017","source":"Turkiye parazitolojii dergisi","url":"https://pubmed.ncbi.nlm.nih.gov/28483727","citation_count":3,"is_preprint":false},{"pmid":"41455928","id":"PMC_41455928","title":"Molecular characterization, identification and enzyme-producing potential of thermophilic bacterial diversity isolated from the Kars sugar factory.","date":"2025","source":"BMC microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/41455928","citation_count":1,"is_preprint":false},{"pmid":"17588148","id":"PMC_17588148","title":"Genetic diversity of local geese of varying productivity and feather color in Kars.","date":"2007","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17588148","citation_count":1,"is_preprint":false},{"pmid":"39625565","id":"PMC_39625565","title":"Investigating the role of KARS in lung adenocarcinoma via single-cell RNA sequencing.","date":"2024","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39625565","citation_count":0,"is_preprint":false},{"pmid":"40032059","id":"PMC_40032059","title":"Proteomic profiling of kars knockout zebrafish larvae.","date":"2025","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/40032059","citation_count":0,"is_preprint":false},{"pmid":"41002930","id":"PMC_41002930","title":"Hyperkinetic Movement Disorder in KARS1-Related Disease: An Illustrative Video-Recorded Case and Narrative Literature Review.","date":"2025","source":"Neurology international","url":"https://pubmed.ncbi.nlm.nih.gov/41002930","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.08.18.670784","title":"<i>VILMIR</i>  is a  <i>trans</i>  -acting long noncoding RNA that enhances the host interferon response in human epithelial cells","date":"2025-08-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.08.18.670784","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.09.675240","title":"Loss of presenilin 2 function age-dependently increases susceptibility to kainate-induced acute seizures and blunts hippocampal kainate-type glutamate receptor expression","date":"2025-09-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.09.675240","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.27.645769","title":"Structural Insights into Kainate Receptor Desensitization","date":"2025-03-31","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.27.645769","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.09.658567","title":"Kmo restricts  <i>Salmonella</i>  in a whole organism infection model by promoting macrophage lysosomal acidification through kainate receptor antagonism","date":"2025-06-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.09.658567","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18338,"output_tokens":3141,"usd":0.051064,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10694,"output_tokens":3585,"usd":0.071547,"stage2_stop_reason":"end_turn"},"total_usd":0.122611,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"KARS1 (lysyl-tRNA synthetase) is expressed in hair cells of zebrafish, chickens, and mice, with strong localization to the spiral ligament region of the cochlea, Deiters' cells, sulcus epithelium, basilar membrane, and spiral limbus surface, consistent with a role in inner-ear aminoacylation.\",\n      \"method\": \"Immunolocalization/expression analysis in cochlear tissues of multiple species\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct localization experiment across multiple species, but functional consequence of cochlear localization not directly demonstrated\",\n      \"pmids\": [\"23768514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"The KARS1 p.R477H mutation alters protein structure (shown by circular dichroism) and releases LysRS from the multiple-synthetase complex (MSC) without affecting dimer-tetramer oligomerization or cellular distribution; p.R477H and p.P505S mutations each reduce tRNALys aminoacylation activity, with a cumulative effect when combined.\",\n      \"method\": \"Enzymatic aminoacylation assays, circular dichroism spectroscopy, gel filtration chromatography, immunofluorescence\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal in vitro methods (enzymatic assay, CD, gel filtration) in a single study demonstrating both structural and catalytic consequences of mutations\",\n      \"pmids\": [\"28887846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"The KARS1 p.Pro228Leu variant impairs mitochondrial translation in patient fibroblasts, causing multiple oxidative phosphorylation deficiency; re-introduction of wild-type mitochondrial KARS (but not the cytosolic isoform) rescued the defect, demonstrating that this variant specifically disrupts the mitochondrial isoform's function.\",\n      \"method\": \"Patient fibroblast molecular characterization, isoform-specific rescue by re-expression, oxidative phosphorylation assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean loss-of-function phenotype with isoform-specific rescue experiment providing mechanistic specificity\",\n      \"pmids\": [\"30252186\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Pathogenic KARS1 variants exhibit reduced aminoacylation (tRNA-charging) enzymatic activity in vitro (shown by aminoacylation assays on purified recombinant protein and in patient lymphoblasts/fibroblasts showing ~50% reduction in enzyme activity), establishing loss of catalytic function as a core pathogenic mechanism.\",\n      \"method\": \"Aminoacylation assays on purified recombinant mutant protein and patient-derived lymphoblasts/fibroblasts\",\n      \"journal\": \"Neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct enzymatic assays on recombinant protein plus patient cell lines with quantitative activity measurements\",\n      \"pmids\": [\"30737337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KARS1 pathogenic variants (p.Pro228Leu and p.Phe291Val) reduce cytoplasmic KARS protein levels in patient cells and decrease interaction of the cytoplasmic isoform with the multiple aminoacyl-tRNA synthetase complex (MSC); both variants also show decreased aminoacylation activity in vitro.\",\n      \"method\": \"Western blot, Co-immunoprecipitation (interaction with MSC), in vitro aminoacylation assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal functional evidence from patient cells (Co-IP showing reduced MSC interaction) plus in vitro enzymatic assay\",\n      \"pmids\": [\"31116475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KARS1 missense mutations reduce enzymatic (aminoacylation) activities of LysRS in Xenopus embryo models, and disrupted LysRS causes abnormal CNS development; LysRS is also noted to act as a non-canonical inducer of immune response with transcriptional activity.\",\n      \"method\": \"Enzymatic assays on mutant LysRS proteins; Xenopus embryo loss-of-function model\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — enzymatic assays plus in vivo Xenopus model, single lab\",\n      \"pmids\": [\"30715177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"KARS1 hearing-impairment mutations (c.1129G>A/p.Asp377Asn and c.517T>C/p.Tyr173His) do not affect LysRS incorporation into the multiple-synthetase complex but alter cytosolic LysRS protein level, tertiary structure, and reduce cytosolic tRNA aminoacylation in vitro; the c.517T>C mutant is completely deficient in charging mitochondrial tRNALys both in vitro and in vivo (yeast model), while c.1129G>A shows less severe mitochondrial charging defect.\",\n      \"method\": \"In vitro aminoacylation assays (cytosolic and mitochondrial tRNALys), gel filtration (MSC incorporation), yeast genetic complementation models\",\n      \"journal\": \"Science China. Life sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods including in vitro reconstitution, yeast in vivo complementation, and MSC interaction assay in one study\",\n      \"pmids\": [\"32189241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A KARS1 mutation (P542R) causes constitutive cytoplasmic mislocalization of LysRS and constitutive activation of MITF (microphthalmia transcription factor), leading to mast cell hyperactivation with increased proinflammatory mediator release; structural dynamics simulations indicate the mutant mimics the active LysRS conformation.\",\n      \"method\": \"Biochemical assays, Western blot, confocal microscopy, cell transfection, cell degranulation assays, prostaglandin D2 secretion measurement, molecular dynamics simulations\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — functional assays (degranulation, mediator secretion) combined with localization and structural modeling, single lab\",\n      \"pmids\": [\"33385443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"KARS1 biallelic variants affect both cytosolic and mitochondrial LysRS isoform function, demonstrated by variable growth defects in yeast complementation models; detrimental effects of two variants were partially rescued by lysine supplementation, suggesting a role for substrate availability in the pathogenic mechanism.\",\n      \"method\": \"Yeast complementation assays for cytosolic and mitochondrial isoforms; lysine supplementation rescue experiment\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via yeast complementation with lysine rescue, single lab\",\n      \"pmids\": [\"33942428\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Kars knock-in mice (p.R477H/p.P505S equivalent) display reduced myelination, oligodendrocyte differentiation arrest, increased caspase-3-mediated apoptosis in oligodendrocytes, reduced aminoacylation and steady-state levels of mitochondrial tRNALys, decreased OXPHOS complex subunit expression, reduced Complex IV activity, decreased ATP production, increased ROS, and abnormal mitochondria in white matter oligodendrocytes; melatonin treatment rescued mitochondrial and oligodendrocyte deficits and restored myelination.\",\n      \"method\": \"CRISPR-Cas9 knock-in mouse model, aminoacylation assays, Complex IV activity assay, ATP/ROS measurement, electron microscopy, immunohistochemistry, melatonin rescue experiment\",\n      \"journal\": \"Journal of pineal research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vivo knock-in model with multiple orthogonal mechanistic assays (enzymatic, bioenergetic, histological, rescue), single lab\",\n      \"pmids\": [\"39087379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Kars knockout zebrafish larvae show differential abundance of 420 proteins versus wildtype; the most enriched pathways affected include ribosome, aminoacyl-tRNA biosynthesis, and hypertrophic cardiomyopathy pathways; specific proteins nars, mybphb, atp2a1l, col6a1, and rps3a are linked to kars deficiency.\",\n      \"method\": \"iTRAQ proteomics on kars knockout zebrafish larvae; parallel reaction monitoring (PRM) validation\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — in vivo knockout with quantitative proteomics, but mechanistic links to individual proteins are correlative\",\n      \"pmids\": [\"40032059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The human KARS1 gene lies immediately adjacent to the RAP1 (TERF2IP) gene in a head-to-head orientation separated by only ~57 nt; both genes share a bidirectional, TATA-less promoter located in the intergenic spacer with downstream promoter elements (DPEs), a conserved arrangement also found in chicken.\",\n      \"method\": \"Genomic locus analysis, promoter activity assays (reporter constructs), EST analysis\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct promoter activity assays with reporter constructs plus genomic analysis, conserved across species\",\n      \"pmids\": [\"14659874\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"KARS1 mutations impair B cell metabolism, specifically reducing mitochondrial numbers and activity in patient B cells, providing a cellular mechanism for the hypogammaglobulinemia observed in KARS1-related disease.\",\n      \"method\": \"Functional analysis of patient B cells (mitochondrial number and activity measurements)\",\n      \"journal\": \"Journal of clinical immunology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single patient cell-based observation, limited mechanistic follow-up reported in abstract\",\n      \"pmids\": [\"37770806\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"KARS1 encodes a dual-localized lysyl-tRNA synthetase (LysRS) that aminoacylates cytosolic and mitochondrial tRNALys with lysine as the first step of protein translation; pathogenic variants reduce aminoacylation activity of one or both isoforms, can disrupt LysRS incorporation into the cytoplasmic multiple aminoacyl-tRNA synthetase complex (MSC), impair mitochondrial translation and oxidative phosphorylation (especially in oligodendrocytes), and in a non-canonical moonlighting role, LysRS translocates to regulate MITF-dependent mast cell activation, with the combination of these canonical and non-canonical dysfunctions underlying a broad disease spectrum including deafness, leukodystrophy, neuropathy, and immune defects.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"KARS1 encodes a dual-localized lysyl-tRNA synthetase (LysRS) that charges both cytosolic and mitochondrial tRNALys with lysine, the committed first step of protein translation, and pathogenic variants converge on loss of this aminoacylation activity as a core disease mechanism [#3, #6]. The cytosolic isoform is incorporated into the multiple aminoacyl-tRNA synthetase complex (MSC), and disease variants act through distinct routes: some (p.R477H) release LysRS from the MSC and reduce charging without altering oligomerization or distribution [#1], while others (p.Pro228Leu, p.Phe291Val) lower cytosolic protein levels and weaken MSC interaction [#4]. Variants can selectively cripple the mitochondrial isoform, impairing mitochondrial translation and producing combined oxidative phosphorylation deficiency, as shown by isoform-specific rescue with the mitochondrial but not cytosolic protein [#2, #6]. In an in vivo knock-in mouse model, compound LysRS deficiency arrests oligodendrocyte differentiation, reduces mitochondrial tRNALys aminoacylation, lowers Complex IV activity and ATP, raises ROS, and impairs myelination [#9]. Beyond its canonical role, a constitutively active LysRS conformation arising from the P542R variant mislocalizes to the cytoplasm and drives MITF-dependent mast cell hyperactivation and proinflammatory mediator release [#7]. These canonical translational and non-canonical signaling functions underlie a phenotypic spectrum spanning hearing impairment, leukodystrophy, and immune defects [#0, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Established that KARS1 is expressed in inner-ear sensory and supporting structures, providing the anatomical rationale for its link to hearing impairment.\",\n      \"evidence\": \"Immunolocalization/expression analysis in cochlear tissues of zebrafish, chicken, and mouse\",\n      \"pmids\": [\"23768514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of cochlear localization not directly demonstrated\", \"Does not establish which isoform mediates the ear-specific requirement\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Resolved that some pathogenic variants act not only by lowering catalysis but by structurally releasing LysRS from the MSC, distinguishing complex-assembly defects from purely enzymatic ones.\",\n      \"evidence\": \"Aminoacylation assays, circular dichroism, gel filtration, and immunofluorescence on p.R477H and p.P505S mutants\",\n      \"pmids\": [\"28887846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not test mitochondrial isoform consequences\", \"In vivo phenotype of MSC release not assessed in this study\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated isoform specificity: a variant can selectively disable the mitochondrial LysRS and cause OXPHOS deficiency, settling that the two isoforms are functionally separable in disease.\",\n      \"evidence\": \"Patient fibroblast characterization with isoform-specific wild-type rescue and OXPHOS assay (p.Pro228Leu)\",\n      \"pmids\": [\"30252186\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific basis of mitochondrial vulnerability not addressed\", \"Did not test cytosolic translation in same cells\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Confirmed reduced aminoacylation as the shared core mechanism across pathogenic variants, quantifying ~50% activity loss in patient cells.\",\n      \"evidence\": \"Aminoacylation assays on purified recombinant protein and patient lymphoblasts/fibroblasts\",\n      \"pmids\": [\"30737337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not connect residual activity level to phenotype severity\", \"Cytosolic vs mitochondrial contribution not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked variant pathogenicity to both reduced cytosolic protein levels and weakened MSC interaction, and connected enzyme loss to abnormal CNS development in vivo.\",\n      \"evidence\": \"Western blot, Co-IP for MSC interaction, in vitro aminoacylation (patient cells); Xenopus loss-of-function embryo model\",\n      \"pmids\": [\"31116475\", \"30715177\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-canonical transcriptional/immune role of LysRS noted but not mechanistically dissected here\", \"Causal chain from MSC loss to neurodevelopmental defect not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed that hearing-impairment variants spare MSC incorporation but differentially impair cytosolic versus mitochondrial tRNALys charging, mapping genotype to isoform-level deficits.\",\n      \"evidence\": \"In vitro aminoacylation of cytosolic and mitochondrial tRNALys, gel filtration, and yeast complementation (p.Asp377Asn, p.Tyr173His)\",\n      \"pmids\": [\"32189241\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cochlear cell-type basis of deafness not resolved\", \"Relationship between charging deficit magnitude and clinical severity unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Uncovered a non-canonical mechanism whereby a variant locks LysRS in an active conformation, driving cytoplasmic mislocalization, MITF activation, and mast cell hyperactivation.\",\n      \"evidence\": \"Biochemical assays, confocal microscopy, degranulation and PGD2 secretion assays, and molecular dynamics simulations (P542R)\",\n      \"pmids\": [\"33385443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; in vivo immune phenotype not validated in patients\", \"Molecular link between LysRS and MITF not biochemically defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established that biallelic variants commonly affect both isoforms and that lysine substrate availability modulates pathogenicity, implicating substrate provision in mechanism.\",\n      \"evidence\": \"Yeast complementation for cytosolic and mitochondrial isoforms with lysine supplementation rescue\",\n      \"pmids\": [\"33942428\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Lysine rescue only partial and not validated in human cells or in vivo\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Provided in vivo mechanistic integration: LysRS deficiency impairs mitochondrial tRNALys charging and bioenergetics in oligodendrocytes, arresting myelination, with melatonin rescuing the deficits.\",\n      \"evidence\": \"CRISPR knock-in mouse (R477H/P505S equivalent), aminoacylation, Complex IV/ATP/ROS assays, electron microscopy, immunohistochemistry, melatonin rescue\",\n      \"pmids\": [\"39087379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Melatonin mechanism of rescue not fully defined\", \"Generalizability to other cell types and variants untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Mapped the proteome-wide consequences of kars loss in vivo, identifying ribosome and aminoacyl-tRNA biosynthesis pathways as most affected.\",\n      \"evidence\": \"iTRAQ proteomics with PRM validation on kars knockout zebrafish larvae\",\n      \"pmids\": [\"40032059\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Links to individual proteins are correlative\", \"Causal role of identified proteins in phenotype untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Extended the mitochondrial mechanism to the immune system, linking impaired B cell mitochondrial function to hypogammaglobulinemia in KARS1 disease.\",\n      \"evidence\": \"Functional analysis of patient B cell mitochondrial number and activity\",\n      \"pmids\": [\"37770806\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single patient cell-based observation with limited mechanistic follow-up\", \"Direct causal link to antibody deficiency not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How specific variant-driven balances of cytosolic-MSC, mitochondrial-translation, and non-canonical MITF dysfunction map onto distinct clinical phenotypes remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying genotype-phenotype model across deafness, leukodystrophy, neuropathy, and immune defects\", \"Molecular basis of the LysRS-MITF signaling axis not defined\", \"Tissue-specific vulnerability mechanisms unexplained\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 2, 3, 6]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [5, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 6, 7]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2, 6, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [3, 6, 10]}\n    ],\n    \"complexes\": [\"multiple aminoacyl-tRNA synthetase complex (MSC)\"],\n    \"partners\": [\"MITF\", \"TERF2IP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}